◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-PERMANENT HIGH

Gabapentin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

For nootropic / cognitive-enhancement use in Dylan, gabapentin is structurally wrong (the name implies GABAergic anxiolysis it cannot deliver), produces dose-dependent cognitive blunting (attention, processing speed, working memory in healthy crossover RCTs), carries a real and increasingly-recognized 2018+ dependence/abuse signal (15-22% misuse prevalence in opioid-using populations, 1% general population, ~5,000 US deaths/year involving gabapentin since 2020), and offers zero cognitive enhancement. The legitimate indications (post-herpetic neuralgia, diabetic peripheral neuropathy, focal epilepsy adjunct, restless legs, alcohol withdrawal taper) are all medical Rx contexts that don't apply to him. Verdict would only flip to OPTIONAL if Dylan develops a documented neuropathic pain syndrome (e.g., the cubital tunnel ulnar neuropathy progresses to chronic neuropathic pain unresponsive to peripheral interventions and BPC-157/TB-500 protocol), at which point it becomes a tool for that specific medical problem, not a cognitive enhancer. Nothing about cognitive-enhancement framing changes the verdict.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-PERMANENT

    for nootropic use. Sedation + cognitive blunting + dependence risk + no cognitive enhancement = wrong tool entirely. Better non-dependence anxiolytics exist (L-theanine, Selank, propranolol PRN, magnesium glycinate, behavioral). The "GABAergic" framing some online sources use to recommend it is factually wrong — it's not GABAergic. OPTIONAL only if a documented neuropathic pain syndrome arises (e.g., cubital tunnel ulnar neuropathy chronifies and fails BPC-157/TB-500 + ergonomic + first-line interventions). At that point it's a medication for that problem, dosed minimally and time-limited with explicit taper plan.

  • 30-50, executive maintenance
    SKIP

    for nootropic use. Same reasoning.

  • 50+, mild cognitive decline
    HARD AVOID

    2024+ observational data (BMJ Group coverage of cohort study) links gabapentin use to increased dementia and cognitive impairment risk in older adults. Even setting aside the causal uncertainty, the cognitive-blunting profile and fall risk make this a poor pick in this group.

  • Anxiety-prone
    SKIP

    for chronic anxiolysis. B-tier social-anxiety RCT exists but better tools (SSRIs for chronic, propranolol for performance, L-theanine + magnesium + behavioral for daily) without dependence liability.

  • High athletic load, tested status
    SKIP

    WADA does not ban gabapentin (irrelevant for Dylan's untested status), but sedation impairs reaction time and recovery training quality.

  • Sleep-disordered
    SKIP

    for sleep tool use. It does sedate, but daridorexant/seltorexant/L-tryptophan/glycine are better-targeted with no dependence. Gabapentin-for-sleep is the wrong tool for the right problem.

  • Recovery-focused (post-injury, post-illness)
    C

    — if there is documented neuropathic pain (e.g., post-surgical nerve pain, postherpetic neuralgia, compressive neuropathy), it has a real role short-term. Otherwise skip.

  • Strength/anabolic-focused
    SKIP

    No anabolic relevance; weight gain is fluid-driven not muscle-driven.

▸ Subjective experience (deep)

At therapeutic doses (300-1200 mg/day, divided TID):

  • Most users report sedation, lightheadedness, and mild ataxia in the first week (the "gabapentin loading" phenomenon).
  • Tolerance to sedation usually develops over 1-2 weeks.
  • Cognitive blunting persists for many users — "fuzzy thinking," word-finding difficulty, slowed processing.
  • No euphoria at therapeutic doses for most users.

At supratherapeutic / abuse doses (1800-4800 mg single oral, or smaller doses snorted):

  • Onset 1-2 hours oral, faster intranasal.
  • Reported: euphoria (described as "weed-like," "drunk-like," "opioid-like" but distinctly milder than opioids), sedation, anxiolysis, sociability, slurred speech, ataxia, dizziness.
  • Highly route- and dose-dependent. Saturable absorption means oral mega-dosing produces non-linear plasma curves; many users snort to bypass the gut transporter limit.
  • Co-administration with opioids, benzodiazepines, or alcohol is the modal pattern in abuse populations — gabapentin alone is rarely the only drug.
  • Comedown: anxiety, irritability, restlessness — hallmarks of α2δ rebound.

Withdrawal (clinical and abuse contexts):

  • Onset: 12 hours to 7 days after abrupt discontinuation. Faster onset with shorter use; gradual onset with chronic use.
  • Symptoms: anxiety, insomnia, sweating, tremor, autonomic instability (tachycardia, hypertension), nausea, restlessness; severe cases include seizures, agitation, hallucinations, delirium reminiscent of benzodiazepine withdrawal.
  • Severity correlates with daily dose and duration of use. Patients on >1800 mg/day for >6 months are highest risk.
  • Treatment: gradual taper over 1-2+ weeks (10-25% reduction per week typical).

For Dylan specifically: even at low therapeutic doses, the cognitive blunting profile is the opposite of what he wants. "Sedation + slowed processing + word-finding lag" in someone whose top priority is "brain — cognitive performance AND brain preservation, co-equal #1." This is a structural mismatch.

▸ Tolerance + cycling deep dive
  • Tolerance to anticonvulsant and analgesic effects: minimal-to-modest at therapeutic doses for the medical indication. Patients on stable doses often maintain efficacy for years.
  • Tolerance to sedation: rapid (1-2 weeks). This is why initial sedation usually wanes.
  • Tolerance to subjective/abuse effects: rapid and profound. Recreational users describe needing escalating doses within weeks to recreate the initial euphoria — classic dependence pharmacology.
  • Recommended cycle: not applicable for medical use (continuous dosing is the protocol). For abuse-prevention rationale: don't start.
  • Reset protocol: taper to discontinuation over 1-2+ weeks; allow ≥4 weeks before any future re-exposure if there's any history of abuse pattern.
▸ Stacking deep dive

Synergistic with

  • (intentionally minimal — synergies here are mostly liabilities)
  • TCAs (amitriptyline, nortriptyline) for neuropathic pain — additive analgesia, both well-established. Watch combined sedation.
  • Duloxetine — additive in DPN per ACCORD-style combination data.

Avoid stacking with

  • opioids — additive respiratory depression; documented mortality signal. Hard avoid for Dylan (not on opioids, but flag for awareness).
  • benzodiazepines — additive CNS depression.
  • phenibut, baclofen, alcohol, GHB — same family of GABAergic / α2δ / GHB-receptor depressants; stack creates respiratory depression / coma risk.
  • pregabalin — same mechanism, redundant.
  • modafinil — directly antagonistic to Dylan's V5 wakefulness goal (gabapentin sedates, modafinil promotes wake).

Neutral / safe co-administration

  • Antacids / aluminum-magnesium reduce gabapentin absorption ~20% — separate by 2 h.
  • No CYP interactions — neutral with most psychiatric and supplement stack components.
  • V4 supplement stack (NAC, magnesium, citicoline, fish oil, etc.) — no PK or PD interactions.
▸ Drug interactions deep dive
  • No CYP induction or inhibition — gabapentin is renally cleared unchanged.
  • Aluminum/magnesium antacids reduce absorption ~20% (dose separation needed).
  • CNS depressants (opioids, benzodiazepines, alcohol, sedating antihistamines, baclofen, GHB, phenibut, pregabalin) — additive sedation, additive respiratory depression. Major safety concern.
  • Morphine specifically increases gabapentin AUC ~44% (mechanism: shared LAT1 affinity? gut motility?) — increases sedation and respiratory risk.
  • Naproxen / NSAIDs modestly increase gabapentin absorption.
  • Hydrocodone, oxycodone, methadone — major dependence + respiratory depression interaction.
  • No oral contraceptive interaction.
  • No warfarin interaction (clinically significant) — convenient for elderly polypharmacy.
▸ Pharmacogenomics
  • No clinically significant CYP polymorphism effects (no CYP metabolism).
  • OCT2 / MATE1 polymorphisms can affect renal clearance modestly but not enough to alter dosing in most cases.
  • 23andMe will not flag anything actionable for gabapentin.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx generic via PCP / telehealth CVS, Walgreens, GoodRx, Mark Cuban Cost Plus Drugs $4-15/month for 300 mg TID High Trivially obtained for legitimate indication; PCP comfort with prescribing is high.
US Rx via pain clinic Pain management physician covered by insurance High For neuropathic pain only.
State-controlled (KY, TN, WV, MI, VA, AL, ND) Same — state Schedule V Same cost High but PDMP-tracked 5-refill / 6-month limit. Dylan is in TBD state — check his state's status before any conversation.
Indian / international online pharmacy Various ~$10-25 for 100 ct Medium Possible but unnecessary — easy via legit US Rx.
Gray market / no Rx Not available — not a research-chem item, US Rx is trivial. — — —

Sourcing-difficulty: easy. Not a barrier in any meaningful sense if a legit medical indication exists.

▸ Biomarkers to track (deep)
  • Baseline (before starting): creatinine, eGFR (renal dose adjust), AUDIT-C if any alcohol use, sedation baseline VAS, depression / suicidal ideation screen (PHQ-9 or C-SSRS), driving fitness self-assessment.
  • During use: eGFR every 6-12 months (especially elderly), weight (edema vs true gain), mood, daytime sedation, fall events, confusion / cognitive complaints.
  • Discontinuation phase: anxiety, insomnia, autonomic symptoms during taper. Have a slow taper plan (not an abrupt-stop plan).
▸ Controversies / open debates Live debate

The Neurontin off-label marketing scandal (Parke-Davis / Warner-Lambert / Pfizer)

This is essential context for understanding gabapentin's reputation among physicians and harm-reduction skeptics. In 2004, Warner-Lambert pleaded guilty and paid $430 million — at the time one of the largest US pharmaceutical settlements ever — for illegally promoting Neurontin for off-label uses (bipolar disorder, RSD, migraine, ADHD, restless legs, etc.) during the 1990s through Parke-Davis-organized "speakers' bureaus," ghostwritten journal articles, and direct payments to physicians. The whistleblower, David Franklin (a former Parke-Davis medical liaison), filed the suit under the False Claims Act — the first off-label promotion case successfully prosecuted under that statute. The 2009 NEJM perspective by Steinman, Bero et al. ("The Neurontin Legacy — Marketing through Misinformation and Manipulation") documented systematic ghostwriting of "scientific" articles to support off-label uses without evidence. Most of the originally-promoted indications (bipolar, ADHD, migraine prophylaxis, RSD) subsequently failed in proper RCTs — Pande's own 2000 monotherapy bipolar trial was negative.

The relevance for Dylan: a lot of "gabapentin works for X" lore on the internet is downstream of paid marketing, not real evidence. When someone tells you "gabapentin is great for anxiety," ask whether the source pre- or post-dates the 2004 settlement. Most positive-but-thin evidence from the 1990s should be discounted.

Mechanism: it's not GABAergic — but the name persists

Patient education materials, Wikipedia summaries, and even some medical reference texts still occasionally describe gabapentin as "GABAergic" or "increasing GABA." This is wrong. The α2δ-1 mechanism has been firmly established since the late 1990s and the gabapentin mechanism is now textbook neuropharmacology. Yet the name keeps the misconception alive — this matters for Dylan because he might encounter "gabapentin works on GABA, take it like phenibut" framing online; both halves of that sentence are wrong.

The 2018+ dependence signal: how serious is it really?

  • Pre-2010: dismissed as "no abuse potential, low dependence."
  • 2010-2017: case reports accumulating, especially in opioid-using populations.
  • 2018-present: multiple population-based cohort studies, CDC MMWR reporting, UK Class C/Schedule 3 reclassification (April 2019), 7 US states Schedule V'ing, FDA Boxed Warning (2019), EU EMA safety review.
  • Current consensus: real dependence syndrome with measurable mortality, primarily in polypharmacy contexts, but also in monotherapy for some users. The Smith 2016 systematic review remains the canonical synthesis; the 2024 Frontiers in Pharmacology longitudinal cohort (Driot et al.) confirmed the prescribing pattern that drives the harm.
  • For Dylan: the dependence signal is real and has hardened in the literature. This is not "internet panic"; it's reflected in regulatory action and mortality statistics.

Where my prior verdict might be wrong

I've parked this as SKIP-PERMANENT for cognitive use. The verdict could be challenged if:

  • A new RCT showed gabapentin produces measurable cognitive enhancement in healthy adults. Doesn't exist; mechanism (reduced glutamate release) is structurally anti-cognitive at relevant doses.
  • Tolerance + dependence signal turned out to be confounded by polypharmacy. Possible at the population level, but individual-case dependence reports are well-characterized.
  • A specific Dylan-relevant indication arose (neuropathic pain from cubital tunnel, post-injury, etc.). Then it shifts to OPTIONAL for that indication, not for nootropic use.

The verdict for nootropic / cognitive-enhancement use is robust.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-PERMANENT (HIGH confidence) for nootropic use. Wrong tool (no GABAergic activity despite name; α2δ-1 mechanism reduces glutamate release → cognitive blunting in healthy users), real dependence signal (15-22% in opioid-using populations, mortality data, 2018+ regulatory action), no cognitive enhancement evidence. OPTIONAL only if a documented neuropathic pain Rx indication arises (e.g., cubital tunnel chronification).
▸ Open questions / gaps Open
  • Does the cubital tunnel ulnar neuropathy progress in a way that creates a real neuropathic pain indication? If yes, gabapentin (or pregabalin, or duloxetine) becomes a legitimate option — at which point the BPC-157/TB-500 protocol should still be tried first (Dylan's preference for healing over masking).
  • Is there a "low-and-bounded" use case (e.g., 100-300 mg pre-bed for sleep latency in late-chronotype migration) where the cognitive blunting is acceptable and the dependence risk is low enough? Not recommended — daridorexant/seltorexant orexin antagonists are better-targeted for sleep onset without α2δ liability or dependence.
  • Are there pharmacogenomic variants (LAT1 / SLC7A5, OCT2) that meaningfully change exposure? Largely no — but this would be checked against 23andMe results in June 2026 if the question ever became live.
▸ Sources (full, with our context)
Back to compact view